ELCC: Adding Eftilagimod Alpha to Pembrolizumab May Crack Secondary Resistance in NSCLC
Recorded Courses
hosted byProjects In Knowledge Inc. (PIK)
hosted byProjects In Knowledge Inc. (PIK)
attend it anywhere online
category
Other Fields, Nursing, Medicine
Biotechnology
price
Free
ELCC: Adding Eftilagimod Alpha to Pembrolizumab May Crack Secondary Resistance in NSCLC is organized by Projects In Knowledge Inc. (PIK).
Release Date: Apr 11, 2023
Termination Date: Apr 10, 2024
Learning Objective(s):
• Summarize recent clinical trial findings utilizing immunotherapy for patients with treatment naïve advanced or metastatic NSCLC.
• Review current recommendations for treatment of patients who develop secondary resistance to IO therapy for NSCLC.
Additional details will be posted as soon as information is available.